*Order all
your Pharmaceutical, Healthcare, Medical & Scientific books at
Amazon
| |
|
|
|
|
|
|
|
|
||||||||||||||||||
|
Categories |
Top 10 global pharmaceutical products (2006)With statistics sourced via IMS Health, below is a listing of the top 10 global pharmaceutical products for 2006 along with links to related articles and sources of further information. Leading global pharmaceutical products 2006
|
|||||||||||||||||
|
|
Launched in August 2000 by
AstraZeneca, in 2006 Nexium (esomeprazole)
achieved global pharmaceutical product sales of $6.7b (1.1% of total global
pharmaceutical sales and a year-over-year sales increase of 16.9%). Nexium
sales contributed to total global Acid Pump Inhibitor sales in 2006 of
$24.1b.
Nexium (esomeprazole) is a proton pump inhibitor (PPI) and works
by blocking acid production in the stomach. Esomeprazole is used to treat
acid-related stomach and throat (osophagus) disorders, such as acid reflux or
GERD and erosive esophagitis. Esomeprazole can decrease excess acid in the
stomach and help to relieve such symptoms as heartburn, swallowing problems,
persistent cough and sleep related problems. NEXIUM is supplied as
Delayed-Release Capsules for oral administration.
Further information: Nexium
(esomeprazole)
|
|
GlaxoSmithKline's (GSK) combination asthma
product Seretide achieved global pharmaceutical sales of $6.3b in 2006 (1% of
total global pharmaceutical sales and a year-over-year sales increase of 10.3%)
and contributed significantly to overall global pharmaceutical respiratory
agent sales of $24.6b. Seretide was launched by GSK in March
1999.
Seretide (Advair) contains a combination of both salmeterol and
fluticasone, and is used as a maintenance treatment to prevent or reduce
wheezing / breathing problems caused by asthma and / or ongoing lung disease,
such as COPD and emphysema. Seretide decreases swelling and relaxes muscles in
the airways, thus controlling the symptoms of breathing problems.
Further information: Seretide
(fluticasone+salmeterol)
|
|
Launched in July 1998 by
Sanofi-Aventis, Plavix (clopidogrel) achieved global
pharmaceutical product sales of $5.8b in 2006 (1% of total global
pharmaceutical sales and a year-over-year sales increase of
-3.4%).
Working by preventing platelets from forming harmful blood
clots, Plavix (clopidogrel) is used to prevent heart attacks and strokes in
patients with a history heart disease, recent heart attack, unstable angina,
recent stroke and / or peripheral vascular disease. . Plavix (clopidogrel),
with it's 'anti-platelet' properties, helps to maintain blood flow.
Further information: Plavix
(clopidogrel)
|
|
Launched as Istin (UK) by
Pfizer in January 1990, and marketed as the generic,
Amlodipine and as Norvasc in North America, this pharmaceutical product had the
5th highest global pharmaceutical sales in 2006 - $5b (0.8% of total global
pharmaceutical sales and a year-over-year sales increase of
-0.5%).
Norvasc (amlodipine) is a calcium channel blocker and is used to
treat hypertension (high blood pressure), chronic stable angina, vasospastic
angina and coronary artery disease. Such treatment of hypertension with Norvasc
(amlodipine) can aid in the prevention of strokes, heart attacks, and kidney
problems.
Norvasc (amlodipine) is a peripheral arterial vasodilator that
acts directly on vascular smooth muscle to cause a reduction in peripheral
vascular resistance and reduction in blood pressure.
Further information: Norvasc
(amlodipine)
Launched by Amgen in 2001, Aranesp
(darbepoetin alfa) had the sixth highest global pharmaceutical sales in 2006 of
$5b (0.8% of total global pharmaceutical sales and a year-over-year sales
increase of 35.6%) and contributing to total global Erythropoietin product
sales of $13.9b.
Aranesp (darbepoetin alfa) is indicated in the
treatment of anemia associated with chronic renal failure and the treatment of
anemia in patients with nonmyeloid malignancies where the anemia is caused by
coadministered chemotherapy treatments. Aranesp (darbepoetin alfa) is an
erythropoiesis stimulating protein, closely related to
erythropoietin.
Further
information: Aranesp (darbepoetin alfa)
Launched by Lilly in October 1996, in 2006 Zyprexa
(olanzapine) achieved global pharmaceutical product sales of $4.7b (0.8% of
total global pharmaceutical sales and a year-over-year sales increase of
-0.4%), contributing to total global Antipsychotics pharmaceutical product
sales of of $18.2b.
Zyprexa (olanzapine) is indicated in the treating
the symptoms of schizophrenia, acute mixed or manic episodes of bipolar I
disorder and for maintenance treatment in bipolar disorder.
Further information: Zyprexa
(olanzapine)
|
|
In 2006, Risperdal (risperidone) achieved
global pharmaceutical sales of $4.6b, contributing to total global
antipsychotic sales of $18.2b (0.8% of total global pharmaceutical sales and a
year-over-year sales increase of Risperdal (risperidone) - 12.3%). Risperdal
was launched by Janssen Cilag in June
1993.
Risperdal (risperidone) is indicated for the treatment of
schizophrenia; short-term treatment of acute manic or mixed episodes associated
with bipolar disorder. Risperdal (risperidone) has an antipsychotic effect
caused by dopamine and serotonin receptor blocking within the central nervous
system.
Further information:
Risperdal (risperidone)
9. Enbrel (etanercept)Launched by Wyeth
in May 2000, Enbrel (etanercept) achieved global pharmaceutical product sales
of $4.5b in 2006 (0.7% of total global pharmaceutical sales and a
year-over-year sales increase of 18.4%) and con
Enbrel (etanercept) is a
type of protein called a tumor necrosis factor (TNF) blocker. Tumor necrosis
factor is made by the body's immune system. In diseases such as rheumatoid
arthritis, juvenile rheumatoid arthritis, ankylosing spondylitis, psoriatic
arthritis, and plaque psoriasis, there is too much TNF in the body.
Further information: Enbrel
(etanercept)
|
|
In 2006, Effexor (venlafaxine) achieved
global pharmaceutical product sales of $4.0b, a year-over-year increase of 2.7%
and overall, contributing 0.7% of total global pharmaceutical
sales.
Effexor (venlafaxine hydrochloride) is indicated for the
treatment of major depressive disorder. The mechanism Effexor (venlafaxine) is
associated with its potentiation of neurotransmitter activity in the central
nervous system.
Further
information: Effexor (venlafaxine)
|
|
|
|
|
|
Get the latest Pharmaceutical drug reviews, reports &
pharmaceutical intelligence
|
| |
|
|
Copyright ©. All rights reserved. Pharmaceutical.org.uk |
|
 |
|
|
Other Pharmaceutical sites: JobsPharm.com | AllAboutMedicalSales.com | Pharmaceutical-Company.co.uk | Pharm.co.uk |
|
 |
|
1. Lipitor (atorvastatin)
Atorvastatin in Lipid
Disorders
